Showing results (591-600 of 3,353) with videos related to
Sort By:
Pageof 336
The Lancet. Oncology|November 19, 2020
Oncology nursing workforce: challenges, solutions, and future strategiesJulia M Challinor, Mohammad R Alqudimat, Tamara O A Teixeira, et al.The Lancet. Oncology|January 9, 2023
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trialEve Rodler, Priyanka Sharma, William E Barlow, et al.The Lancet. Oncology|June 28, 2021
Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort studyAntonio Braga, Gabriela Paiva, Ehsan Ghorani, et al.The Lancet. Oncology|June 4, 2021
The effect of non-AIDS-defining cancers on people living with HIVElizabeth Y Chiao, Anna Coghill, Darya Kizub, et al.The Lancet. Oncology|December 14, 2020
Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry studyLaura M Fernandez, Guilherme P São Julião, Nuno L Figueiredo, et al.The Lancet. Oncology|November 27, 2022
Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk SyndromesJosé Garcia-Pelaez, Rita Barbosa-Matos, Silvana Lobo, et al.The Lancet. Oncology|December 1, 2022
International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemicVictor Ho-Fun Lee, Marlinda Adham, Wala Ben Kridis, et al.The Lancet. Oncology|December 1, 2022
Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumabRuben Malmberg, Michiel Zietse, Daphne W Dumoulin, et al.The Lancet. Oncology|July 7, 2022
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trialRobin Kate Kelley, Lorenza Rimassa, Ann-Lii Cheng, et al.Pageof 336